Journal
ECLINICALMEDICINE
Volume 21, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.eclinm.2020.100332
Keywords
Surrogate endpoints; FDA; Breast cancer; Progression-free survival; Overall survival; Response rates; Event-free survival; Disease-free survival; Pathological complete
Categories
Funding
- Arnold Ventures
- Harvard -MIT Center for Regulatory Science
Ask authors/readers for more resources
Background: In July 2018, the FDA first published a table listing all surrogate measures that it has used, and may accept for future use, in regulatory approval. However, the strength of surrogacy for those measures was not formally assessed. Using the case example of breast cancer, we aimed to evaluate the strength of correlation of surrogate measures listed in the FDA's Table with overall survival. Methods: This cross-sectional study of the FDA's Table of Surrogate Endpoints was conducted in May 2019. All surrogate measures listed in the FDA table as appropriate for accelerated or regular approval for breast cancer were extracted. We identified studies evaluating the correlation of treatment benefit in the surrogate with treatment benefit in overall survival and extracted results from the correlation analysis. Findings: Five surrogate endpoints were listed for breast cancer in the FDA website: pathological complete response rates (pCR), event-free survival (EFS), disease-free survival (DFS), objective response rates (ORR), and progression-free survival (PFS), of which pCR was listed as appropriate only for accelerated approval, while the rest were considered appropriate for accelerated or regular approval. No correlation study evaluated the correlation of treatment effects on EFS with that on OS. The results from correlation studies evaluating pCR, DFS, ORR, and PFS suggest that the treatment effects on none of these surrogate measures were strongly correlated with treatment effects on OS (r<0.85 or R-2 < 0.7, except for DFS in HER2 positive early breast cancer (R-2 = 0.75) Interpretation: Using breast cancer as an example, we evaluated the underlying evidence for the surrogate endpoints for solid tumors listed in the FDA's Table of Surrogate Endpoints and found weak or missing correlations of treatment effects on these surrogates with treatment effects on OS. Surrogate measures should be predictive of clinical benefit to be useful in supporting regular FDA approval. (C) 2020 The Authors. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available